Abstract
Pancreatic cancer is still one of the malignancies with a very poor prognosis
worldwide. In the recent past, the gut microbiota has been shown to have a role in
pancreatic cancer patients’ survival and response to the therapy. Out of the possible
mechanisms, the role of gut microbiota in shaping the microbial composition of
pancreatic tumor and its effect on intra-tumor immune modulation has emerged as a
potential therapeutic strategy. Modulation of gut microbiota for targeting pancreatic
cancer initiation, progression and therapy could be achieved through different
processes like treatment through faecal microbiota transplantation (FMT), antibiotics,
prebiotics, probiotics, and synbiotics. In the recent past, various clinical and
experimental pieces of evidence have demonstrated the efficacy of probiotics in cancer
prevention, treatment and management. In this chapter, efforts have been directed
towards summarizing the prospects and challenges associated with the use of probiotics
and probiotics-derived products against pancreatic cancer.